DK1533304T3 - Amidderivat - Google Patents

Amidderivat

Info

Publication number
DK1533304T3
DK1533304T3 DK03738555.6T DK03738555T DK1533304T3 DK 1533304 T3 DK1533304 T3 DK 1533304T3 DK 03738555 T DK03738555 T DK 03738555T DK 1533304 T3 DK1533304 T3 DK 1533304T3
Authority
DK
Denmark
Prior art keywords
amide derivative
het
halogen
present
formula
Prior art date
Application number
DK03738555.6T
Other languages
English (en)
Inventor
Tetsuo Asaki
Yukiteru Sugiyama
Taisuke Hamamoto
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30003594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1533304(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of DK1533304T3 publication Critical patent/DK1533304T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03738555.6T 2002-06-28 2003-06-27 Amidderivat DK1533304T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002189269 2002-06-28
JP2002305146 2002-10-18
JP2002377937 2002-12-26
PCT/JP2003/008192 WO2004002963A1 (ja) 2002-06-28 2003-06-27 アミド誘導体及び医薬

Publications (1)

Publication Number Publication Date
DK1533304T3 true DK1533304T3 (da) 2010-03-22

Family

ID=30003594

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03738555.6T DK1533304T3 (da) 2002-06-28 2003-06-27 Amidderivat

Country Status (15)

Country Link
US (1) US7494997B2 (da)
EP (1) EP1533304B1 (da)
JP (1) JP4552650B2 (da)
CN (1) CN100343237C (da)
AT (1) ATE447560T1 (da)
AU (1) AU2003246100A1 (da)
BR (1) BRPI0312288B8 (da)
CA (1) CA2490907C (da)
DE (1) DE60329918D1 (da)
DK (1) DK1533304T3 (da)
ES (1) ES2337995T3 (da)
MX (1) MXPA04012845A (da)
PT (1) PT1533304E (da)
RU (1) RU2315043C2 (da)
WO (1) WO2004002963A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7375175B2 (en) 2002-08-19 2008-05-20 National Starch And Chemical Investment Holding Corporation Dispersions containing living radicals
EP1585723A2 (en) * 2003-01-17 2005-10-19 Wisconsin Alumni Research Foundation Modified retinoid compounds and their uses
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
CA2529090A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors
EP1661904A1 (en) 2003-08-22 2006-05-31 Meiji Seika Kaisha Ltd. Novel azalide and azalactam derivatives and process for the production of the same
HUE034712T2 (hu) * 2003-12-25 2018-02-28 Nippon Shinyaku Co Ltd Amidszármazék és gyógyszer
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
EP1786799B1 (en) * 2004-09-09 2012-07-04 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
US20100048597A1 (en) * 2006-12-22 2010-02-25 Novartis Ag Organic Compounds and Their Uses
JP5559043B2 (ja) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
JP5710251B2 (ja) 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規ヘテロ環化合物およびその使用
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
WO2009124037A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
MX2011009310A (es) 2009-03-06 2011-10-13 Novartis Ag Uso de derivados de pirimidilaminobenzamida para el tratamiento de trastornos mediados por la cinasa que contiene un motivo de cierre de leucina y alfa esteril (zak).
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
RU2012120901A (ru) 2009-10-23 2013-12-10 Новартис Аг Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
RU2672553C2 (ru) * 2012-03-14 2018-11-16 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения и способы лечения лейкемии
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
CA2922657C (en) 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
WO2015076801A1 (en) * 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted triazine bmi-1 inhibitors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108602800B (zh) * 2017-01-20 2019-08-27 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
CN108699039B (zh) 2017-01-20 2019-12-20 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
JP2022523562A (ja) * 2019-03-05 2022-04-25 ホンイー アンド アソシエイツ エルエルシー 神経変性疾患および癌の治療のための化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (da) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
EP1533304B1 (en) 2009-11-04
DE60329918D1 (de) 2009-12-17
BR0312288A (pt) 2005-04-12
JP4552650B2 (ja) 2010-09-29
ES2337995T3 (es) 2010-05-03
JPWO2004002963A1 (ja) 2005-10-27
BRPI0312288B1 (pt) 2019-01-02
RU2315043C2 (ru) 2008-01-20
US20060014742A1 (en) 2006-01-19
CA2490907C (en) 2010-08-24
EP1533304A1 (en) 2005-05-25
BRPI0312288B8 (pt) 2021-05-25
MXPA04012845A (es) 2005-02-24
US7494997B2 (en) 2009-02-24
CN1678590A (zh) 2005-10-05
AU2003246100A1 (en) 2004-01-19
RU2005102098A (ru) 2005-09-20
EP1533304A4 (en) 2006-10-18
PT1533304E (pt) 2010-02-08
CN100343237C (zh) 2007-10-17
WO2004002963A1 (ja) 2004-01-08
CA2490907A1 (en) 2004-01-08
ATE447560T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
DE60329918D1 (de) Amidderivat
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
EA200200942A1 (ru) Фармацевтические композиции, содержащие производные 3-аминоазетидина, новые производные и способ их получения
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
RS51477B (en) SUBSTITUTED ALKYLAMINE DERIVATIVES AND PROCEDURES FOR THEIR USE
FR2842804B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DK1426371T3 (da) Tetrazoyloximderivater og agrokemikalier der indeholder samme som aktivstof
MY150630A (en) Amide derivative and insecticide containing the same
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
IL147651A0 (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
WO2002074726A3 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
ZA200810739B (en) Pesticide containing novel pyridyl-methanamine derivative or its salt
ATE555781T1 (de) Thioamide und deren salze und beide enthaltende cytokin-bildungsinhibitoren
DK1452528T3 (da) Xanthinoxidaserinhibitorer
DE60302558D1 (de) 5-substituierte alkylaminopyrazol-derivative als pestizide
DE60116589D1 (de) Fungizide Phenylamidinderivative
SE0103710D0 (sv) Compounds
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
TW200628153A (en) Novel compounds
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
EP1357124A4 (en) HETEROCYCLIC COMPOUNDS AND COMPOSITIONS IMPROVING CEREBRAL FUNCTIONS CONTAINING THESE AS ACTIVE INGREDIENTS
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
CY1110898T1 (el) Νεα παραγωγα πυριδινοκαρβοξυλικου οξεος ή αλατα αυτων
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие